Human African Trypanosomiasis (Sleeping Sickness) : The Road to Elimination Revisited-Achievements and Remaining Challenges

As it is a goal to eliminate human African trypanosomiasis (HAT; sleeping sickness) as a public health problem by 2020 and interrupt transmission by 2030, this is a good moment to reflect on what we have achieved, what we want to achieve, and what could get in our way. HAT has a reputation for spect...

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (280 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993545792404498
ctrlnum (CKB)5400000000041155
(oapen)https://directory.doabooks.org/handle/20.500.12854/68624
(EXLCZ)995400000000041155
collection bib_alma
record_format marc
spelling Burri, Christian edt
Human African Trypanosomiasis (Sleeping Sickness) The Road to Elimination Revisited-Achievements and Remaining Challenges
Human African Trypanosomiasis
Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
1 electronic resource (280 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
As it is a goal to eliminate human African trypanosomiasis (HAT; sleeping sickness) as a public health problem by 2020 and interrupt transmission by 2030, this is a good moment to reflect on what we have achieved, what we want to achieve, and what could get in our way. HAT has a reputation for spectacular reappearances, and the latest peak of 40,000 reported and over 300,000 estimated cases only dates back to 1998. Efforts of the WHO and partners as well as the development of simpler and much better-tolerated treatments, improved diagnostics, and vector control tools made it possible to reduce this number by 95%. Case identification and confirmation remain complex and require specific skills, treatment remains error-prone and reports on long-term survivors have emerged, and the relevance of the animal reservoir for T. b. gambiense HAT needs clarification. In addition, to win the “end game” against this massively stigmatized disease, the human factor will play a key role. This Special Issue addresses many of the burning topics about disease elimination in its 12 research and 7 review articles and one case study. The papers critically reflect the approaches used, investigate the mentioned challenges, and propose novel approaches and interventions from various points of view.
English
Medicine bicssc
Epidemiology & medical statistics bicssc
(+)-spectaline
iso-6-spectaline
Trypanosoma brucei rhodesiense
autophagy
apoptosis
cross-talk
trypanosomosis
iron
transferrin
transferrin receptor
nutritional immunity
flagellar pocket
Human African Trypanosomiasis (HAT)
mydriasis
neurological signs
eradication
re-emergence
human African trypanosomiasis
treatment
melarsoprol
adverse event
encephalopathy
human leukocyte antigen
association study
disease elimination
disease eradication
frontline workers
DR Congo
mobile screening
qualitative methods
sequelae
serology
oligosymptomatic HAT
product development partnerships
research and development
medical innovation
donor policy
African trypanosomiasis
sleeping sickness
trypanosoma brucei
drugs
drug resistance
history
human Africa trypanosomiasis
fexinidazole
home-based treatment
patient-centred care
Uganda
elimination
T. b. gambiense
g-HAT
T. b. rhodesiense
r-HAT
neglected tropical diseases
Trypanosoma brucei
drug discovery
high-throughput screening
blood-brain barrier
brain permeability
pharmacology
phenotypic drug screening
Haemoparasites
animal reservoirs
Trypanosoma growth inhibitors
chemotherapy
pafuramidine
acoziborole
African sleeping sickness
development of treatment
suramin
medical history
political history
clinical research
health system strengthening
South Sudan
diagnosis
symptoms
treatment-seeking
case detection
embodiment
expertise
serendipity
CATT positive serological suspects
active follow-up strategy
3-03928-963-2
3-03928-964-0
Burri, Christian oth
language English
format eBook
author2 Burri, Christian
author_facet Burri, Christian
author2_variant c b cb
author2_role Sonstige
title Human African Trypanosomiasis (Sleeping Sickness) The Road to Elimination Revisited-Achievements and Remaining Challenges
spellingShingle Human African Trypanosomiasis (Sleeping Sickness) The Road to Elimination Revisited-Achievements and Remaining Challenges
title_sub The Road to Elimination Revisited-Achievements and Remaining Challenges
title_full Human African Trypanosomiasis (Sleeping Sickness) The Road to Elimination Revisited-Achievements and Remaining Challenges
title_fullStr Human African Trypanosomiasis (Sleeping Sickness) The Road to Elimination Revisited-Achievements and Remaining Challenges
title_full_unstemmed Human African Trypanosomiasis (Sleeping Sickness) The Road to Elimination Revisited-Achievements and Remaining Challenges
title_auth Human African Trypanosomiasis (Sleeping Sickness) The Road to Elimination Revisited-Achievements and Remaining Challenges
title_alt Human African Trypanosomiasis
title_new Human African Trypanosomiasis (Sleeping Sickness)
title_sort human african trypanosomiasis (sleeping sickness) the road to elimination revisited-achievements and remaining challenges
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2020
physical 1 electronic resource (280 p.)
isbn 3-03928-963-2
3-03928-964-0
illustrated Not Illustrated
work_keys_str_mv AT burrichristian humanafricantrypanosomiasissleepingsicknesstheroadtoeliminationrevisitedachievementsandremainingchallenges
AT burrichristian humanafricantrypanosomiasis
status_str n
ids_txt_mv (CKB)5400000000041155
(oapen)https://directory.doabooks.org/handle/20.500.12854/68624
(EXLCZ)995400000000041155
carrierType_str_mv cr
is_hierarchy_title Human African Trypanosomiasis (Sleeping Sickness) The Road to Elimination Revisited-Achievements and Remaining Challenges
author2_original_writing_str_mv noLinkedField
_version_ 1787548485705269248
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05163nam-a2201321z--4500</leader><controlfield tag="001">993545792404498</controlfield><controlfield tag="005">20231214133130.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000041155</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/68624</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000041155</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Burri, Christian</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Human African Trypanosomiasis (Sleeping Sickness)</subfield><subfield code="b">The Road to Elimination Revisited-Achievements and Remaining Challenges</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Human African Trypanosomiasis </subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (280 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">As it is a goal to eliminate human African trypanosomiasis (HAT; sleeping sickness) as a public health problem by 2020 and interrupt transmission by 2030, this is a good moment to reflect on what we have achieved, what we want to achieve, and what could get in our way. HAT has a reputation for spectacular reappearances, and the latest peak of 40,000 reported and over 300,000 estimated cases only dates back to 1998. Efforts of the WHO and partners as well as the development of simpler and much better-tolerated treatments, improved diagnostics, and vector control tools made it possible to reduce this number by 95%. Case identification and confirmation remain complex and require specific skills, treatment remains error-prone and reports on long-term survivors have emerged, and the relevance of the animal reservoir for T. b. gambiense HAT needs clarification. In addition, to win the “end game” against this massively stigmatized disease, the human factor will play a key role. This Special Issue addresses many of the burning topics about disease elimination in its 12 research and 7 review articles and one case study. The papers critically reflect the approaches used, investigate the mentioned challenges, and propose novel approaches and interventions from various points of view.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidemiology &amp; medical statistics</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">(+)-spectaline</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">iso-6-spectaline</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Trypanosoma brucei rhodesiense</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autophagy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">apoptosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cross-talk</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">trypanosomosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">iron</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transferrin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transferrin receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nutritional immunity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">flagellar pocket</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Human African Trypanosomiasis (HAT)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mydriasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurological signs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">eradication</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">re-emergence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human African trypanosomiasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melarsoprol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adverse event</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">encephalopathy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human leukocyte antigen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">association study</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">disease elimination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">disease eradication</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">frontline workers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DR Congo</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mobile screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">qualitative methods</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sequelae</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">serology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oligosymptomatic HAT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">product development partnerships</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">research and development</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medical innovation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">donor policy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">African trypanosomiasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sleeping sickness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">trypanosoma brucei</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">history</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human Africa trypanosomiasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fexinidazole</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">home-based treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">patient-centred care</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Uganda</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">elimination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T. b. gambiense</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">g-HAT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T. b. rhodesiense</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">r-HAT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neglected tropical diseases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Trypanosoma brucei</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug discovery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">high-throughput screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">blood-brain barrier</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">brain permeability</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phenotypic drug screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Haemoparasites</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">animal reservoirs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Trypanosoma growth inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pafuramidine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acoziborole</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">African sleeping sickness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">development of treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">suramin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medical history</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">political history</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical research</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">health system strengthening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">South Sudan</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">symptoms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment-seeking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">case detection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">embodiment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">expertise</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">serendipity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CATT positive serological suspects</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">active follow-up strategy</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03928-963-2</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03928-964-0</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Burri, Christian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:43:30 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338020210004498&amp;Force_direct=true</subfield><subfield code="Z">5338020210004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338020210004498</subfield></datafield></record></collection>